ABIVAX Société Anonyme (ABVX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

ABIVAX Société Anonyme (ABVX) closed at USD 87.98 on 2026-10-14, a change of -6.6 % over the past year, with a market capitalization of USD 8.06B.

ABIVAX Société Anonyme recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

ABIVAX Société Anonyme key figures

Previous close

USD 87.98 (2026-10-14)

1-year change

-6.6 %

Market cap

USD 8.06B

Enterprise value

USD 6.97B

P/E ratio (trailing)

-14.88

P/E ratio (forward)

-23.97

EPS (trailing)

-6.21

EPS (forward)

-3.85

PEG ratio

n/a

Price to book

17.97

Revenue growth

-6.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.73

Employees

98

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for ABIVAX Société Anonyme and compare it with other stocks.